Review



dctn1  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology dctn1
    Dctn1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dctn1/pm40404107-44-17-24?v=Santa+Cruz+Biotechnology
    Average 93 stars, based on 10 article reviews
    dctn1 - by Bioz Stars, 2026-07
    93/100 stars

    Images



    Similar Products

    dctn1  (Proteostasis Therapeutics)
    86
    Proteostasis Therapeutics dctn1
    Hypothesis for the dynamic progression of disease based on ALSFRS-R scores in patients with fALS. Schematic illustration summarizing the dynamic changes in disease severity and functional scores that occur with disease progression. The fALS patients with mutations in <t>DCTN1</t> , ANXA11 , HNRNPA1 , SIGMAR1 , and TARDBP tended to have an older age of onset, whereas those with mutations in P/LP genes, especially ALS2 , FUS , SOD1 , and OPTN , had a younger age of onset. The fALS patients with an earlier onset, longer diagnostic delay, higher BMI, fewer first-degree relatives, and spinal onset exhibited a slow progression of disease. By contrast, patients who had a later onset, shorter diagnostic delay, lower BMI, more first-degree relatives, bulbar onset, and a history of smoking and drinking exhibited rapid progression. ALSFRS-R: ALS functional rating scale-revised; BMI: body mass index; fALS: familial amyotrophic lateral sclerosis; P/LP: pathogenic/likely pathogenic.
    Dctn1, supplied by Proteostasis Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dctn1/pmc13211834-9-0-10?v=Proteostasis+Therapeutics
    Average 86 stars, based on 1 article reviews
    dctn1 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    dctn1  (R&D Systems)
    93
    R&D Systems dctn1
    Hypothesis for the dynamic progression of disease based on ALSFRS-R scores in patients with fALS. Schematic illustration summarizing the dynamic changes in disease severity and functional scores that occur with disease progression. The fALS patients with mutations in <t>DCTN1</t> , ANXA11 , HNRNPA1 , SIGMAR1 , and TARDBP tended to have an older age of onset, whereas those with mutations in P/LP genes, especially ALS2 , FUS , SOD1 , and OPTN , had a younger age of onset. The fALS patients with an earlier onset, longer diagnostic delay, higher BMI, fewer first-degree relatives, and spinal onset exhibited a slow progression of disease. By contrast, patients who had a later onset, shorter diagnostic delay, lower BMI, more first-degree relatives, bulbar onset, and a history of smoking and drinking exhibited rapid progression. ALSFRS-R: ALS functional rating scale-revised; BMI: body mass index; fALS: familial amyotrophic lateral sclerosis; P/LP: pathogenic/likely pathogenic.
    Dctn1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dctn1/10__1172_slash_jci198418-135-113-120?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    dctn1 - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    rabbit anti dctn1  (Proteintech)
    93
    Proteintech rabbit anti dctn1
    Hypothesis for the dynamic progression of disease based on ALSFRS-R scores in patients with fALS. Schematic illustration summarizing the dynamic changes in disease severity and functional scores that occur with disease progression. The fALS patients with mutations in <t>DCTN1</t> , ANXA11 , HNRNPA1 , SIGMAR1 , and TARDBP tended to have an older age of onset, whereas those with mutations in P/LP genes, especially ALS2 , FUS , SOD1 , and OPTN , had a younger age of onset. The fALS patients with an earlier onset, longer diagnostic delay, higher BMI, fewer first-degree relatives, and spinal onset exhibited a slow progression of disease. By contrast, patients who had a later onset, shorter diagnostic delay, lower BMI, more first-degree relatives, bulbar onset, and a history of smoking and drinking exhibited rapid progression. ALSFRS-R: ALS functional rating scale-revised; BMI: body mass index; fALS: familial amyotrophic lateral sclerosis; P/LP: pathogenic/likely pathogenic.
    Rabbit Anti Dctn1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dctn1/pm41044645-64-4-6?v=Proteintech
    Average 93 stars, based on 1 article reviews
    rabbit anti dctn1 - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    dctn1  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology dctn1
    Hypothesis for the dynamic progression of disease based on ALSFRS-R scores in patients with fALS. Schematic illustration summarizing the dynamic changes in disease severity and functional scores that occur with disease progression. The fALS patients with mutations in <t>DCTN1</t> , ANXA11 , HNRNPA1 , SIGMAR1 , and TARDBP tended to have an older age of onset, whereas those with mutations in P/LP genes, especially ALS2 , FUS , SOD1 , and OPTN , had a younger age of onset. The fALS patients with an earlier onset, longer diagnostic delay, higher BMI, fewer first-degree relatives, and spinal onset exhibited a slow progression of disease. By contrast, patients who had a later onset, shorter diagnostic delay, lower BMI, more first-degree relatives, bulbar onset, and a history of smoking and drinking exhibited rapid progression. ALSFRS-R: ALS functional rating scale-revised; BMI: body mass index; fALS: familial amyotrophic lateral sclerosis; P/LP: pathogenic/likely pathogenic.
    Dctn1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dctn1/pm40404107-44-17-24?v=Santa+Cruz+Biotechnology
    Average 93 stars, based on 1 article reviews
    dctn1 - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    cdna constructs of dctn1-ret  (Promega)
    90
    Promega cdna constructs of dctn1-ret
    Hypothesis for the dynamic progression of disease based on ALSFRS-R scores in patients with fALS. Schematic illustration summarizing the dynamic changes in disease severity and functional scores that occur with disease progression. The fALS patients with mutations in <t>DCTN1</t> , ANXA11 , HNRNPA1 , SIGMAR1 , and TARDBP tended to have an older age of onset, whereas those with mutations in P/LP genes, especially ALS2 , FUS , SOD1 , and OPTN , had a younger age of onset. The fALS patients with an earlier onset, longer diagnostic delay, higher BMI, fewer first-degree relatives, and spinal onset exhibited a slow progression of disease. By contrast, patients who had a later onset, shorter diagnostic delay, lower BMI, more first-degree relatives, bulbar onset, and a history of smoking and drinking exhibited rapid progression. ALSFRS-R: ALS functional rating scale-revised; BMI: body mass index; fALS: familial amyotrophic lateral sclerosis; P/LP: pathogenic/likely pathogenic.
    Cdna Constructs Of Dctn1 Ret, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dctn1/pm40155036-36-7-15?v=Promega
    Average 90 stars, based on 1 article reviews
    cdna constructs of dctn1-ret - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    fish for dctn1-ret  (GeneticLab Co Ltd)
    90
    GeneticLab Co Ltd fish for dctn1-ret
    Hypothesis for the dynamic progression of disease based on ALSFRS-R scores in patients with fALS. Schematic illustration summarizing the dynamic changes in disease severity and functional scores that occur with disease progression. The fALS patients with mutations in <t>DCTN1</t> , ANXA11 , HNRNPA1 , SIGMAR1 , and TARDBP tended to have an older age of onset, whereas those with mutations in P/LP genes, especially ALS2 , FUS , SOD1 , and OPTN , had a younger age of onset. The fALS patients with an earlier onset, longer diagnostic delay, higher BMI, fewer first-degree relatives, and spinal onset exhibited a slow progression of disease. By contrast, patients who had a later onset, shorter diagnostic delay, lower BMI, more first-degree relatives, bulbar onset, and a history of smoking and drinking exhibited rapid progression. ALSFRS-R: ALS functional rating scale-revised; BMI: body mass index; fALS: familial amyotrophic lateral sclerosis; P/LP: pathogenic/likely pathogenic.
    Fish For Dctn1 Ret, supplied by GeneticLab Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dctn1/pm40155036-45-2-7?v=GeneticLab+Co+Ltd
    Average 90 stars, based on 1 article reviews
    fish for dctn1-ret - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    anti dctn1  (Proteintech)
    94
    Proteintech anti dctn1
    Hypothesis for the dynamic progression of disease based on ALSFRS-R scores in patients with fALS. Schematic illustration summarizing the dynamic changes in disease severity and functional scores that occur with disease progression. The fALS patients with mutations in <t>DCTN1</t> , ANXA11 , HNRNPA1 , SIGMAR1 , and TARDBP tended to have an older age of onset, whereas those with mutations in P/LP genes, especially ALS2 , FUS , SOD1 , and OPTN , had a younger age of onset. The fALS patients with an earlier onset, longer diagnostic delay, higher BMI, fewer first-degree relatives, and spinal onset exhibited a slow progression of disease. By contrast, patients who had a later onset, shorter diagnostic delay, lower BMI, more first-degree relatives, bulbar onset, and a history of smoking and drinking exhibited rapid progression. ALSFRS-R: ALS functional rating scale-revised; BMI: body mass index; fALS: familial amyotrophic lateral sclerosis; P/LP: pathogenic/likely pathogenic.
    Anti Dctn1, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dctn1/pmc11746963-89-13-14?v=Proteintech
    Average 94 stars, based on 1 article reviews
    anti dctn1 - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Hypothesis for the dynamic progression of disease based on ALSFRS-R scores in patients with fALS. Schematic illustration summarizing the dynamic changes in disease severity and functional scores that occur with disease progression. The fALS patients with mutations in DCTN1 , ANXA11 , HNRNPA1 , SIGMAR1 , and TARDBP tended to have an older age of onset, whereas those with mutations in P/LP genes, especially ALS2 , FUS , SOD1 , and OPTN , had a younger age of onset. The fALS patients with an earlier onset, longer diagnostic delay, higher BMI, fewer first-degree relatives, and spinal onset exhibited a slow progression of disease. By contrast, patients who had a later onset, shorter diagnostic delay, lower BMI, more first-degree relatives, bulbar onset, and a history of smoking and drinking exhibited rapid progression. ALSFRS-R: ALS functional rating scale-revised; BMI: body mass index; fALS: familial amyotrophic lateral sclerosis; P/LP: pathogenic/likely pathogenic.

    Journal: Neural Regeneration Research

    Article Title: Comprehensive clinical and genetic architecture of familial amyotrophic lateral sclerosis in China: A 15-year cohort study with 302 families

    doi: 10.4103/NRR.NRR-D-24-00701

    Figure Lengend Snippet: Hypothesis for the dynamic progression of disease based on ALSFRS-R scores in patients with fALS. Schematic illustration summarizing the dynamic changes in disease severity and functional scores that occur with disease progression. The fALS patients with mutations in DCTN1 , ANXA11 , HNRNPA1 , SIGMAR1 , and TARDBP tended to have an older age of onset, whereas those with mutations in P/LP genes, especially ALS2 , FUS , SOD1 , and OPTN , had a younger age of onset. The fALS patients with an earlier onset, longer diagnostic delay, higher BMI, fewer first-degree relatives, and spinal onset exhibited a slow progression of disease. By contrast, patients who had a later onset, shorter diagnostic delay, lower BMI, more first-degree relatives, bulbar onset, and a history of smoking and drinking exhibited rapid progression. ALSFRS-R: ALS functional rating scale-revised; BMI: body mass index; fALS: familial amyotrophic lateral sclerosis; P/LP: pathogenic/likely pathogenic.

    Article Snippet: DCTN1 , 2p13.1 , AD , NM_004082.4 , 4.50 , Proteostasis, retrograde axonal transport , Tenuous.

    Techniques: Functional Assay, Biomarker Discovery, Diagnostic Assay